Objective To investigate the regulatory effects of Bushen Huoxue Decoction on iron metabolism and ferroptosis in patients with postmenopausal osteoporosis (PMOP), and to analyze the correlations of hepcidin with bone metabolism and clinical efficacy. Methods A total of 60 PMOP patients were randomly assigned to an observation group or a control group (n=30 each). The control group received oral alfacalcidol plus alendronate combined with exercise therapy. On this basis, the observation group was additionally treated with Bushen Huoxue Decoction for 3 months. Lumbar spine and hip bone mineral density (BMD) were measured before and after treatment. Iron metabolism indices [hepcidin, serum ferritin, transferrin, transferrin saturation (TSAT)], ferroptosis-related indices [glutathione peroxidase 4 (GPX4), reduced glutathione (GSH), malondialdehyde (MDA)] and bone metabolism indices [25-hydroxyvitamin D3, parathyroid hormone (PTH), type I collagen C-terminal telopeptide (CTX), procollagen type I N-terminal propeptide (PINP), serum calcium, serum phosphorus, and tartrate-resistant acid phosphatase (TRACP)] were determined. Clinical efficacy was evaluated based on changes in BMD and pain symptoms. Results BMD of the lumbar spine and hip increased in both groups compared with baseline, with greater improvements in the observation group (P<0.05). In the observation group, hepcidin levels were significantly decreased, whereas serum ferritin, transferrin and TSAT were significantly increased compared with baseline and the control group (P<0.05). Levels of GPX4 and GSH were markedly elevated and MDA was markedly reduced (P<0.05), showing more pronounced changes than in the control group. The increases in 25- (OH) D3 and PINP and the decreases in CTX, PTH and TRACP were also more significant in the observation group (P<0.05), while serum calcium and phosphorus remained relatively stable in both groups. Correlation analysis showed that hepcidin was negatively correlated with lumbar, femoral neck and total hip BMD, and positively correlated with CTX and MDA; GPX4 was positively correlated with BMD and negatively correlated with CTX; clinical efficacy was negatively correlated with hepcidin and positively correlated with GPX4 and GSH (all P<0.01). Conclusion Bushen Huoxue Decoction can downregulate hepcidin, improve disturbed iron metabolism and inhibit ferroptosis in PMOP patients, thereby protecting osteoblasts, promoting bone formation and increasing BMD. Hepcidin may serve as a potential therapeutic target in PMOP, providing a new mechanistic basis and evaluation index for the prevention and treatment of osteoporosis with traditional Chinese medicine.
Key words
Bushen Huoxue decoction /
postmenopausal osteoporosis /
hepcidin /
iron metabolism /
ferroptosis
{{custom_sec.title}}
{{custom_sec.title}}
{{custom_sec.content}}
References
[1] 王茜茜, 沈睿, 王俊杰, 等. 绝经后骨质疏松症患者运动干预的最佳证据总结[J]. 中国全科医学, 2023, 26(9): 1151-1158.
[2] SHOBACK D, ROSEN CJ, BLACK DM, et al. Pharmacological management of osteoporosis in postmenopausal women: an endocrine society guideline update[J]. J Clin Endocrinol Metab, 2020, 105(3): dgaa048.
[3] 中华医学会骨质疏松和骨矿盐疾病分会. 原发性骨质疏松症诊疗指南 (2022)[J]. 中华内分泌代谢杂志, 2023, 39(5): 377-406.
[4] WU X, FANG X, LU F, et al.An update on the role of ferroptosis in the pathogenesis of osteoporosis[J]. EFORT Open Rev, 2024, 9(8): 712-722.
[5] TANG D, CHEN X, KANG R, et al.Ferroptosis: molecular mechanisms and health implications[J]. Cell Res, 2021, 31(2): 107-125.
[6] 刘禄林, 江小伟, 廖直斌, 等. 铁调素敲除对雄性小鼠铁代谢及骨代谢影响的实验研究[J]. 中国骨质疏松杂志, 2023, 29(02): 157-161.
[7] 郭奎廷, 高宏伟, 冷向阳. 绝经后骨质疏松症中医研究进展[J]. 长春中医药大学学报, 2022, 38(05): 581-584.
[8] 汤志利, 欧阳建江, 徐鑫. 补肾活血汤治疗绝经后骨质疏松症的临床效果评价[J]. 江西医药, 2021, 56(06): 854-855.
[9] 谢玉城, 吴官保, 冯帅华, 等. 补肾活血汤联合阿仑膦酸钠对绝经后骨质疏松患者临床疗效及免疫调控因子的影响[J]. 中国医学创新, 2022, 19(13): 67-70.
[10] 浦冬青, 刘志勇, 冯丹丹, 等. 补肾活血法预防芳香化酶抑制剂所致骨丢失的机制[J]. 中国骨质疏松杂志, 2024, 30(08): 1127-1132.
[11] 张亚兰, 周杰, 程真, 等. 绝经后骨质疏松症早期筛查及干预研究进展[J]. 中华健康管理学杂志, 2024, 18(2): 146-150.
[12] JIANG Z, WANG H, QI G, et al.Iron overload-induced ferroptosis of osteoblasts inhibits osteogenesis and promotes osteoporosis: an in vitro and in vivo study[J]. IUBMB Life, 2022, 74(11): 1052-1069.
[13] MAHESHWARI S, SINGH A, VERMA A.Ferroptosis: a frontier in osteoporosis[J]. Horm Metab Res, 2024, 56(9): 625-632.